IDEXX Laboratories, Inc.

Equities

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
543.4 ^USD	+0.46%		+8.51%	-2.09%

05-14	Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $596 From $620	MT
05-02	BNP Paribas Adjusts Price Target on IDEXX Laboratories to $641 From $653	MT

IDEXX Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 01, 2024 at 04:14 pm

IDEXX Laboratories, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 964.1 million compared to USD 900.2 million a year ago. Net income was USD 235.58 million compared to USD 214.05 million a year ago.

Basic earnings per share from continuing operations was USD 2.84 compared to USD 2.58 a year ago. Diluted earnings per share from continuing operations was USD 2.81 compared to USD 2.55 a year ago.

Latest news about IDEXX Laboratories, Inc.

Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $596 From $620	05-14	MT
BNP Paribas Adjusts Price Target on IDEXX Laboratories to $641 From $653	05-02	MT
Goldman Sachs Adjusts Price Target on IDEXX Laboratories to $600 From $675	05-02	MT
Stifel Adjusts Price Target on IDEXX Laboratories to $520 From $570	05-02	MT
Barclays Adjusts Price Target on IDEXX Laboratories to $570 From $655	05-02	MT
Redburn Atlantic Adjusts Price Target on IDEXX Laboratories to $500 From $460	05-02	MT
Wall Street: heaviness prevails after a volatile episode	05-01	CF
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999.	05-01	CI
IDEXX Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Transcript : IDEXX Laboratories, Inc., Q1 2024 Earnings Call, May 01, 2024	05-01
IDEXX Laboratories' Q1 Earnings, Revenue Increase	05-01	MT
Earnings Flash (IDXX) IDEXX LABORATORIES Posts Q1 Revenue $964.1M, vs. Street Est of $965.8M	05-01	MT
Idexx Laboratories, Inc. Revises Earnings Guidance for 2024	05-01	CI
North American Morning Briefing : Traders Wait for -2-	05-01	DJ
BofA Securities Cuts Price Target on IDEXX Laboratories to $595 From $600, Maintains Neutral Rating	04-30	MT
Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board	04-01	MT
Elanco appoints two directors after settling with activist Ancora	04-01	RE
Elanco appoints two directors to its board after agreement with Ancora	04-01	RE
Idexx Laboratories: Superior growth prospects	03-11
Idexx Laboratories Insider Sold Shares Worth $790,427, According to a Recent SEC Filing	03-07	MT
Idexx Laboratories Insider Sold Shares Worth $4,525,596, According to a Recent SEC Filing	03-07	MT
Transcript : IDEXX Laboratories, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-04-2024 11:00 AM	03-04
Ancora seeks four board seats at Elanco amid push for changes	02-29	RE
Transcript : IDEXX Laboratories, Inc. Presents at Bank of America 2024 Animal Health Virtual Summit, Feb-29-2024 10:50 AM	02-29
Ancora seeks four board seats at Elanco amid push for changes, sources say	02-29	RE

Chart IDEXX Laboratories, Inc.

Duration

Period

More charts

Company Profile

IDEXX Laboratories, Inc. is a world leader in the design, development and marketing of diagnostic test instruments for animal health monitoring and analysis of dairy products and water. Net sales break down by area of application as follows: - veterinary diagnoses for pets (91.6%); - water quality analysis (4.6%); - veterinary diagnoses for livestock and poultry (3.3%): solutions that help detect infectious diseases in ruminants, pigs, poultry and horses. The group also offers test solutions for dairy products; - other (0.5%). Net sales by source of income break down between product sales (57.1%) and services (42.9%). Net sales are distributed geographically as follows: the United States (65.3%), Canada (4.1%), Americas (2.3%), Germany (4.1%), the United Kingdom (3.3%), France (2.7%), Italy (1.5%), Spain (1.4%), Switzerland (0.9%), the Netherlands (0.8%), Europe/Middle East/Africa (4.8%), Australia (2.6%), Japan (2.1%), China (1.2%) and Asia/Pacific (2.9%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-29 - Stifel Jaws & Paws Conference

Related indices

S&P 500

More about the company